Replies to post #120 on NeuroSense Therapeutics Ltd (NRSN)

[runncoach]

You were off somewhere between 30% and 600%. Do you know how much a patient pays a year for ALS medication? That would be quite a bit of difference in sales revenues. Either way potential sales, if ever, are quite a ways off no doubt. If Biogen takes over the indication would likely be much quicker through any approval process. JMHO